Clinical Trial Update: Eversense® Non-adjunctive Use Post Approval Study [NA]

View source ↗

Summary

A post-approval study is ongoing to evaluate non-adjunctive use of the Eversense CGM in diabetes patients; the trial is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Eversense

Snippet

Sponsor: Senseonics, Inc. | Conditions: Diabetes | NA | Status: ACTIVE_NOT_RECRUITING